This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial
The #NephJC chat on IgA nephropathy and the significance of crescents was quite exciting, and we were fortunate to have Dr Jonathan Barratt, one of the authors, join us for the EU chat. Thanks again to JASN for providing full text access!
The Oxford pathology classification does not include crescents in its assessment of IgA nephropathy. This was due to the low number of crescents on the initial cohort. This week's NephJC looks at a recent attempt to right this oversight.